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Novel Aza Peptide Inhibitors and Active-Site
Probes of Papain-Family Cysteine Proteases
Steven H. L. Verhelst,[a] Martin D. Witte,[a, b] Shirin Arastu-Kapur,[a]
Marko Fonovic,[a, c] and Matthew Bogyo*[a]
Introduction
The papain family or CA clan is one of the largest subfamilies
of the cysteine proteases. Interest in this family continues to
grow as a result of recent advances in our understanding of
their involvement in several physiological and pathological
processes.[1] Specifically, members of the lysosomal cysteine ca-
ACHTUNGTRENNUNGthep ACHTUNGTRENNUNGsins have been shown to be involved in various human
systemic diseases such as rheumatoid arthritis[2] and tumor in-
vasion.[3] Additionally, papain-family proteases play an impor-
tant role in many types of parasitic infections.[4] For example,
the human malaria parasite, Plasmodium falciparum, expresses
three papain-like cysteine proteases: falcipains 1, 2, and 3. The
latter two primarily facilitate the degradation of hemoglobin
during normal catabolism, while the function of falcipain 1 is
not as clear. Falcipain 1 function has in part been defined
through the use of selective inhibitors.[5]
Cysteine proteases also serve as ideal targets for develop-
ment of small-molecule therapeutic agents. Cysteine-protease
inhibitors have gained considerable attention over the last
couple of decades and many classes of compounds are cur-
rently in human clinical trials for a number of diseases. The ma-
jority of cysteine-protease inhibitors make use of reactive func-
tional groups that selectively modify the key active-site cys-
teine residue.[6,7] Examples of well-characterized inhibitors in-
clude peptidyl aldehydes and nitriles, which can react with the
active-site cysteine residue to form reversible covalent adducts,
as well as vinylsulfones, peptidyl epoxysuccinates, halomethyl
ketones, and acyloxymethyl ketones (AOMKs), all of which
form irreversible covalent adducts between enzyme and inhibi-
tor.
In addition to their use for potential therapeutic applica-
tions, several classes of covalent inhibitors have been
ACHTUNGTRENNUNGequipped with a variety of tags that allow them to be used as
activity-based probes (ABPs). Such probes can specifically
modify active proteases in complex proteomes thereby allow-
ing the regulation of protease activity to be monitored with
simple biochemical methods.[8] ABPs also allow affinity purifica-
tion of corresponding enzymes.[8] Our laboratory and others
have extensively investigated epoxysuccinates,[5,9–11] vinyl sul-
fones,[9,12] and, more recently, AOMKs[13] as ABPs. While these
probes have proven useful for a number of biological applica-
tions, they all have limitations resulting from complex synthet-
ic methods or scope of targets that can be analyzed. For these
reasons we set out to further diversify the current cysteine-pro-
tease probe set by examining the utility of other reactive func-
tional groups and peptide scaffolds.
We chose to focus on the O-acyl hydroxamate reactive
group as it has been shown to form selective covalent bonds
with the active site of cysteine proteases.[14] This class of com-
pounds can be synthesized by using simple chemistry that is
compatible with solid-phase peptide synthesis and allows ex-
tensive diversification of structural elements that access active-
site residues on both sides of the key catalytic cysteine residue.
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Recent characterization of multiple classes of functionalized aza-
peptides as effective covalent inhibitors of cysteine proteases
prompted us to investigate O-acyl hydroxamates and their aza-
peptide analogues for use as activity-based probes (ABPs). We
report here a new class of azaglycine-containing O-acylhydroxa-
mates that form stable covalent adducts with target proteases.
This allows them to be used as ABPs for papain family cysteine
proteases. A second class of related analogues containing a
novel O-acyl hydroxyurea warhead was found to function as co-
valent inhibitors of papain-like proteases. These inhibitors can be
easily synthesized on solid support, which allows rapid optimiza-
tion of compounds with improved selectivity and potency for a
given target enzyme. We present here one such optimized inhibi-
tor that showed selective inhibition of falcipain 1, a protease of
the malaria-causing parasite, Plasmodium falciparum.
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Previous efforts to develop O-acyl hydroxamates (A, Scheme 1)
have resulted in the development of several commercially
available inhibitors of papain-family enzymes, such as cathep-
ACHTUNGTRENNUNGsin inhibitor III (Scheme 1).[14] Mechanistic studies indicate that
inhibition of the protease results in substitution of the acyl
group by the active-site cysteine thus producing a covalent S
N bond (Scheme 1).[15] We chose to develop synthetic methods
that allowed incorporation of this validated reactive functional
group onto the N terminus of a standard peptide scaffold. The
resulting O-acyl hydroxyurea (B) mimics the structure of the
peptide epoxysuccinates and could be obtained by using
simple solid-phase chemistry.
One potential limitation of O-acyl hydroxyureas is the place-
ment of the reactive group at the N terminus of the peptide;
this results in loss of a P1 element, thereby limiting reactivity
to many CD clan cysteine proteases and reducing possible di-
versity sites for optimization of selectivity. To overcome some
of these limitations and examine the functional properties of
the O-acyl hydroxamate in the context of other linkages to a
peptide scaffold, we developed the synthesis of azapeptide O-
acyl hydroxamates (C, Scheme 1). The incorporation of the aza
functional group allowed the reactive functional group to be
attached at the C-terminal end of the peptide. Azapeptides
have recently been validated for use as CD clan pro-
tease inhibitors when functionalized with epoxysuc-
cinate[16] and Michael-acceptor warheads.[17]
Here, we report the synthesis of two novel cys-
teine-protease inhibitor scaffolds based on the O-
acyl hydroxamate reactive group: O-acyl hydroxy-
ACHTUNGTRENNUNGureas (B) and azaglycine O-acyl hydroxamates (C ;
Scheme 1). Azapeptide O-acyl hydroxamates are
direct analogues of the original inhibitor A, and
were found to possess considerably higher activity
against ca ACHTUNGTRENNUNGthep ACHTUNGTRENNUNGsins. Furthermore, these compounds
showed stable covalent labeling of recombinant ca-
ACHTUNGTRENNUNGthep ACHTUNGTRENNUNGsins. The O-acyl hydroxyureas, in which the re-
active group was placed at the N-terminal end of a peptide,
were readily accessible by solid-phase peptide chemistry and
proved to be effective inhibitors of caACHTUNGTRENNUNGthep ACHTUNGTRENNUNGsin cysteine proteas-
es. The selectivity of all compounds could be fine-tuned by ad-
justment of the amino acid in the P2 position. How-
ever, as a consequence of the different reactivities of
the warheads and the stability of the covalent
enzyme–inhibitor complexes, only a derivative of the
novel warhead (C) proved to be suitable as an ABP.
Results and Discussion
Synthesis
In order to validate the azapeptide O-acyl hydroxa-
mate warhead, we initially synthesized an azapep-
tide analogue of the previously published O-acyl hy-
droxamate caACHTUNGTRENNUNGthep ACHTUNGTRENNUNGsin inhibitor III (Scheme 1).[14] The
hydrophobic P2 residue in combination with a gly-
cine P1 element provided selectivity for the papain
subfamily of cysteine proteases. In MW4, the glycine
residue was substituted by its aza counterpart; this
resulted in the novel warhead B (Scheme 1). In addi-
tion, the carbobenzoxy (Cbz) group was replaced by
a N-acetyltyrosine that facilitated the construction of
an ABP by introduction of a 125I radiolabel.
The synthesis of MW4 is outlined in Scheme 2. In short,
properly protected dipeptide methyl ester 1 was converted to
carbazate 2, followed by installation of the warhead in a three
step, two-pot procedure. Isocyanate 3, formed in situ by using
carbonyldiimidazole, was treated with hydroxylamine to give
compound 4 in 44% yield. Acylation of the hydroxyl function
with p-anisoyl chloride resulted in protected inhibitor 5. Finally,
deprotection of the tyrosine side chain with 95% TFA and
ACHTUNGTRENNUNGpurification by HPLC afforded MW4 in 21% yield.
To enable rapid synthesis of MW4 and its analogues, the fea-
sibility of (semi)solid-phase synthesis was examined. We rea-
soned that the oxygen of the hydroxylamine moiety would be
a suitable handle for attachment to a solid support. This strat-
egy only required the final acylation and deprotection of
amino acid side chains to be executed in solution after elonga-
tion of the peptide part and cleavage from the resin.
Thus, N-Fmoc hydroxylamine was loaded onto chlorotrityl
resin as described,[18] deprotected with piperidine (20%), and
Scheme 1. Left : ca ACHTUNGTRENNUNGthep ACHTUNGTRENNUNGsin inhibitor III containing an O-acyl hydroxamate reactive group
and the two novel warheads O-acyl hydroxyurea (B) and azaglycine O-acyl hydroxamate
(C). Right: the mechanism of cysteine-protease inactivation by O-acyl hydroxamates (A).
Scheme 2. Reagents and conditions: a) Hydrazine (60 equiv), MeOH, reflux, overnight.
b) Carbonyldiimidazole (6 equiv), DMF, 4 h. c) Hydroxylamine (10 equiv), DIEA (10 equiv),
DMF. d) p-Anisoyl chloride (1.9 equiv), pyridine (2 equiv), THF, 4 8C, 2 h. e) TFA/TIS/H2O
(95:2.5:2.5), 1 h.
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treated with carbonyldiimidazole. It was then treated with
ACHTUNGTRENNUNGhydrazine to furnish functionalized resin 7 (Scheme 3). Next,
solid-phase peptide synthesis was performed by using DIC and
HOBt as condensating agents. After capping of the amino ter-
minus by using acetic anhydride and cleavage from the resin,
which was mediated with TFA (1%), the resulting free hydroxyl
function was acylated with anisoylchloride. Full side-chain
ACHTUNGTRENNUNGdeprotection was achieved with 95% TFA, after which HPLC
ACHTUNGTRENNUNGpurification yielded the desired inhibitors.
Scheme 4 lists the compounds (MW4, MW20, MW21) ob-
tained by this method, which vary in the P2 amino-acid side
chain. The same strategy could be employed to synthesize
control compounds MW2 and MW22 containing the O-acyl hy-
droxamate warhead. Instead of carbonyldiimidazole and hydra-
zine, Fmoc–glycine was coupled to the resin-bound hydroxyl-
ACHTUNGTRENNUNGamine, followed by elongation by using similar protocols as
ACHTUNGTRENNUNGdescribed.
At this point, we turned our attention to the design of an O-
acyl hydroxamate-like warhead at the N terminus of a peptide.
This strategy would allow on-resin acylation of the hydroxyl-
ACHTUNGTRENNUNGamine functional group (i.e. , formation of the warhead), which
renders further synthetic steps in solution unnecessary. The
Scheme 3. Reagents and conditions: a) step 1: piperidine/DMF (1:4), 15 min; step 2: carbonyldiimidazole (6 equiv), CH2Cl2, 3 h; step 3: hydrazine (60 equiv),
DMF, 1 h. b) Solid-phase peptide synthesis by using: step 1: Fmoc–amino acid (3 equiv), DIC (3 equiv), HOBt (3 equiv), 2 h; step 2: piperidine/DMF (1:4),
15 min; step 3: final capping with Ac2O (10 equiv), DIEA (10 equiv), DMF, 15 min. c) 1% TFA in DCM. d) p-Anisoyl chloride (1.9 equiv), pyridine (2 equiv), THF,
4 8C, 2 h. e) TFA/TIS/H2O (95:2.5:2.5), 1 h.
Scheme 4. Overview of the synthesized inhibitors and ABPs with the different warheads A) O-acyl hydroxamate, B) O-acyl hydroxyurea, and C) azaglycine O-
acylhydroxamate.
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particular sequence of immobilized peptide 12 (Scheme 5) was
chosen for its direct analogy to DCG-04, a previously validated
ABP for papain-family cysteine proteases.[11]
Treatment of the free N terminus of the immobilized peptide
with carbonyldiimidazole at room temperature gave hydantoin
13 (Scheme 5). The formation of this type of structure has pre-
viously been described in the synthesis of resin-bound azapep-
tides.[19] However, hydantoin formation could be completely
abolished by treatment of CD I with the free amino terminus of
the resin-bound peptide at 4 8C for 5 min. To complete the for-
mation of N-hydroxyurea 14, the resin was washed with DMF
and treated overnight with hydroxylamine hydrochloride in
the presence of DIEA. Finally, the free hydroxyl was acylated
and probes were cleaved from the resin with TFA (95%) fol-
lowed by HPLC purification (42–52% overall yield).
Evaluation of inhibitors
We initially tested representative examples of each of the war-
heads as inhibitors of purified cathepin cysteine proteases.
Table 1 shows the kinetic inhibition constants determined by
using previously described protocols.[13b] Interestingly, the aza-
glycine O-acyl hydroxamate (MW4) was considerably more
potent against both ca ACHTUNGTRENNUNGthep ACHTUNGTRENNUNGsins B and L than the original O-
acyl hydroxamate (MW2). The novel O-acyl hydroxyurea
(MW6bio) showed increased selectivity for caACHTUNGTRENNUNGthep ACHTUNGTRENNUNGsin L com-
pared to the other two analogues (MW2, MW4).
To evaluate the different warheads in a more physiologically
relevant setting, we performed competition-binding studies
with crude homogenates of rat liver, which contain a number
of characterized caACHTUNGTRENNUNGthep ACHTUNGTRENNUNGsin-protease activities.[10] Rat-liver ho-
mogenate was incubated with increasing concentrations of
MW2, MW4, and MW6. After incubation for 30 min the residual
caACHTUNGTRENNUNGthep ACHTUNGTRENNUNGsin activity was determined by treatment with radiola-
beled ABP DCG-04[11] followed by analysis of samples by SDS-
Scheme 5. Reagents and conditions: a) solid-phase peptide synthesis. b) step 1: piperidine/DMF (1:4), 15 min; step 2: carbonyldiimidazole (6 equiv), DMF,
room temperature. c) step 1: piperidine/DMF (1:4), 15 min; step 2: carbonyldiimidazole (6 equiv), DMF, 4 8C, 5 min; step 3: hydroxylamine (10 equiv), DIEA
(10 equiv), DMF, overnight. d) p-Anisoyl chloride (1.9 equiv), pyridine (2 equiv), THF, 4 8C, overnight. e) TFA/TIS/H2O (95:2.5:2.5), 1 h.
Table 1. Inactivation constants Kass [m
1 s1] for bovine ca ACHTUNGTRENNUNGthep ACHTUNGTRENNUNGsin B and
human ca ACHTUNGTRENNUNGthep ACHTUNGTRENNUNGsin L.
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PAGE. The resulting data were
quantified by using image analy-
sis software. Concentrations at
which 50% of the enzyme activi-
ty was inhibited (apparent IC50
values) are given in Table 2.
Interestingly, the azaglycine-
containing inhibitor, MW4,
showed nearly ten-times higher
potency for all the labeled ca-
ACHTUNGTRENNUNGthep ACHTUNGTRENNUNGsins compared to the origi-
nal O-acyl hydroxamate MW2.
MW6, containing the novel O-
acyl hydroxyurea warhead, dis-
played similar inhibitory potency
as MW2.
The selectivity of MW2 for ca-
ACHTUNGTRENNUNGthep ACHTUNGTRENNUNGsin B was fivefold lower
than the aza-analogue MW4. On
the other hand, MW6 shows a
slight preference for cathep-
ACHTUNGTRENNUNGsin Z. This difference in selectivi-
ty can be explained by a combi-
nation of the nature of the war-
head and P2 position.
To confirm that these inhibi-
tors could be optimized to target specific proteases, we syn-
thesized a series of compounds with variation of the P2 posi-
tion. These compounds were screened for inhibition of falci-
pain 1, a papain-fold cysteine protease found in the human
malaria parasite P. falciparum. Inhibitors were designed by
using previously reported P2 residues that conferred selectivity
for falcipain 1.[5] Accordingly, MW20 was synthesized with a P2
leucine, which displays general affinity for all three falcipains.
MW21, MW22, and MW23 were synthesized with 4-methylphe-
nylalanine as the P2 element (Scheme 4). This structural ele-
ment has previously been shown to induce selectivity for falci-
pain 1.[5]
Compounds (caACHTUNGTRENNUNGthep ACHTUNGTRENNUNGsin inhibitor III, the previously reported
epoxysuccinyl-based falcipain 1 inhibitor YA29,[5] and MW20–
23) were screened by using competition-binding assays in
crude cellular extracts from P. falciaparum. This assay allowed
quantification of potency and selectivity of each compound for
the falcipain targets. Lysates were incubated with serial dilu-
tions of inhibitor for 30 min, and residual protease activity was
monitored by addition of radiolabeled DCG-04 and analyzed
with SDS-PAGE. Two typical sets of results are depicted in
Figure 1. These data confirm that MW21 has a much higher se-
lectivity for falcipain 1 than the leucine-containing analogue,
MW20.
Quantification of the gel data through densometry allowed
the calculation of the apparent IC50 values (Table 3). YA29
showed low micromolar and selective activity against falci-
pain 1. Commercially available caACHTUNGTRENNUNGthep ACHTUNGTRENNUNGsin inhibitor III and aza-
peptide O-acyl hydroxamate MW20 displayed high nanomolar
activity—a significant increase in potency compared to YA29.
However, no selectivity for any of the falcipains was observed.
Installation of 4-methylphenylalanine in the P2 position, as in
MW21 and MW22, restored falcipain 1 selectivity while retain-
ing the overall increased potency relative to YA29. Although
less potent, MW23 retained considerable selectivity for falci-
pain 1; this supports the importance of the P2 position in the
design of falcipain 1 specific inhibitors.
Covalent modification
To gain more insight in the mechanism of inhibition of the
novel warheads, we subjected four compounds (MW2, MW4,
MW6, and caACHTUNGTRENNUNGthep ACHTUNGTRENNUNGsin inhibitor III) to kinetic measurements. To
determine if all compounds form stable covalent linkages with
target proteases we first treated purified ca ACHTUNGTRENNUNGthep ACHTUNGTRENNUNGsins with a
100-fold excess of the inhibitors, removed the compounds
with repeated dilution/filtration steps, and then measured re-
sidual activity with a fluorogenic substrate. For both cathep-
ACHTUNGTRENNUNGsin B and L, no recovery of enzymatic activity was observed
(Figure 2). This result clearly indicates an irreversible mode of
inhibition, which could be a result of covalent attachment to
the active site. To further corroborate this, caACHTUNGTRENNUNGthep ACHTUNGTRENNUNGsin L was
Table 2. Apparent IC50 values of inhibitors for different ca ACHTUNGTRENNUNGthep ACHTUNGTRENNUNGsins in rat-liver homogenates.
Compound IC50 [mm] Selectivity
Ca ACHTUNGTRENNUNGthep ACHTUNGTRENNUNGsin Z Ca ACHTUNGTRENNUNGthep ACHTUNGTRENNUNGsin B Ca ACHTUNGTRENNUNGthep ACHTUNGTRENNUNGsin H Ca ACHTUNGTRENNUNGthep ACHTUNGTRENNUNGsin J/C
MW2 1.1 0.47 >5 >5 cat B (2.3-fold)
MW4 0.17 0.013 0.45 0.95 cat B (13-fold)
MW6 0.13 0.33 >5 >5 cat Z (2.5-fold)
Figure 1. Competition experiment in lysate of P. falciparum by using decreasing concentrations of the indicated
inhibitor. Radiolabeled general cysteine protease ABP DCG-04 was added to monitor remaining falcipain activity.
MW21 appears to be more selective for falcipain 1 than MW20.
Table 3. Apparent IC50 values [mm] of inhibitors for falcipains.
Inhibitor Falcipain 1 Falcipain 2/3 Selectivity
YA-29 2.0 >25 >13
cathespin 0.33 0.43 1.3
inhibitor III
MW20 0.094 0.068 0.7
MW21 0.073 1.6 22
MW22 0.064 1.0 16
MW23 1.8 >25 >13
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ACHTUNGTRENNUNGincubated with an excess of MW2, MW4, or MW6bio and ana-
lyzed by MALDI-TOF. The spectra revealed that the molecular
ion of the treated enzyme had shifted to higher molecular
weight compared to an untreated sample (see Supporting In-
formation). Unfortunately, lack of resolution and accuracy pro-
hibited the identification of the exact nature of the adduct.
However, in line with previous reports,[15] it is likely that the
peptide part of the inhibitor was covalently attached to the
enzyme through a SN bond.
Activity-based probes
The covalent nature of warheads A–C prompted us to investi-
gate their utility as ABPs. To test the ability of the compounds
to directly label caACHTUNGTRENNUNGthep ACHTUNGTRENNUNGsins, the tyrosine residues of MW2,
MW4, and MW6 were subjected to radio-iodination as de-
scribed previously.[11] Surprisingly, incubation of purified ca-
ACHTUNGTRENNUNGthep ACHTUNGTRENNUNGsin B or rat-liver homogenates with the resulting radiola-
beled probes did not show any labeling of ca ACHTUNGTRENNUNGthep ACHTUNGTRENNUNGsin proteases
(data not shown). This lack of labeling by radiolabeled probes
was found to be the result of decomposition of inhibitors
under iodination conditions, as observed by LC-MS analysis of
inhibitors modified with a stable iodine isotope.
Alternatively, ABPs were obtained by synthesizing the biotin-
ylated derivatives MW2bio, MW4bio, and MW6bio (Scheme 4).
In the first two compounds, an extra aminohexanoic acid
spacer and an (e-biotinyl)lysine were incorporated at the N-ter-
minal end of the corresponding inhibitor. Labeling of caACHTUNGTRENNUNGthep-
ACHTUNGTRENNUNGsin B (Figure 3A) was performed by incubation with the three
biotinylated probes (10 mm) and the control DCG-04 probe
(0.1 mm) at pH 5.5. Before loading onto a SDS-PAGE gel, sam-
ples were exposed either to reducing (pH 6.8, 150 mm DTT,
100 8C, 2 min) or nonreducing (pH 6.8, RT) conditions. As ex-
pected from its modest activity against caACHTUNGTRENNUNGthep ACHTUNGTRENNUNGsin B in competi-
tion and kinetic experiments, MW2 proved to be a weak probe
(lanes 1 and 5). MW4, which displayed higher activity in previ-
ous experiments, showed strong labeling of caACHTUNGTRENNUNGthep ACHTUNGTRENNUNGsin B (lanes
2 and 6). Interestingly, the covalent modification formed be-
tween MW6 and the active-site cysteine was not stable when
it was boiled in the presence of DTT (lane 3 vs. 7). Possibly, the
“mercapto–urea” protease–ABP adduct was cleaved under re-
ductive conditions. The lack of caACHTUNGTRENNUNGthep ACHTUNGTRENNUNGsin B labeling by MW6
was also observed when low concentrations of DTT were in-
cluded in the reaction buffer; this illustrates the high instability
of the modification (data not shown).
Ca ACHTUNGTRENNUNGthep ACHTUNGTRENNUNGsin L (Figure 3B) showed similar results as ca ACHTUNGTRENNUNGthep-
ACHTUNGTRENNUNGsin B. Sensitivity of the active-site cysteine to oxidation re-
quired the use of a DTT containing reaction buffer during all
experiments. As a result, no labeling with MW6 was observed
(lanes 3 and 7). The warhead of MW6 is therefore less suitable
for general use in ABPs. On the other hand, MW4 shows effec-
tive labeling of both caACHTUNGTRENNUNGthep ACHTUNGTRENNUNGsins and represents a novel war-
head for use in activity-based proteomics.
Figure 3. Labeling experiments with ca ACHTUNGTRENNUNGthep ACHTUNGTRENNUNGsin B or L. A) Ca ACHTUNGTRENNUNGthep ACHTUNGTRENNUNGsin B
(~100 ng) was incubated with ABP (10 mm for MW2-6bio; 0.1 mm for DCG-
04) at pH 5.5 for 30 min, separated by gel electrophoresis, transferred to ni-
trocellulose, and blotted for biotin. MW6bio appears to be unstable under
reducing conditions. B) The experiment for ca ACHTUNGTRENNUNGthep ACHTUNGTRENNUNGsin L was performed in
the same manner at pH 5.5 in the presence of DTT (2 mm). The blurry bands
in the left panels are due to the nondenaturing conditions used prior to gel
loading.
Figure 2. Ca ACHTUNGTRENNUNGthep ACHTUNGTRENNUNGsin B and L become irreversibly inhibited by all tested com-
pounds. Untreated protease gives rapid cleavage of a fluorescent substrate
(solid black graph), whereas treated proteases, after removal of excess inhib-
itor, remain inactivated (baseline graphs) ; AU=arbitrary units of fluores-
cence.
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Conclusion
In this paper, we present two novel cysteine-protease inhibitor
scaffolds based on the O-acyl hydroxamate reactive group. The
first comprises an azaglycine O-acyl hydroxamate, for which a
semisolid-phase synthesis was devised. These compounds are
efficient inhibitors of papain-family proteases and form stable
covalent adducts with their targets.
Selectivity for other cysteine-protease families might be fur-
nished by introduction of a P1 element. For example, a P1 as-
partate could furnish reactivity against caspases, which are
members of the CD clan of cysteine proteases. These com-
pounds can be accessed by solid-phase synthesis by using a
recent procedure in which azapeptide probes are attached to
the resin through their P1 side-chain linkage.[20]
The second type of inhibitors, comprising the O-acyl hy-
ACHTUNGTRENNUNGdroxy ACHTUNGTRENNUNGurea warhead, could be fully synthesized on resin, thus
presenting a significant advantage over the other inhibitors.
Although mass spectrometry data support the covalent
nature of inhibition for all warheads, the complex resulting
from O-acyl hydroxyureas is not stable enough for analysis by
SDS-PAGE. The azaglycine O-acyl hydroxamates, however,
proved to be suitable for labeling different caACHTUNGTRENNUNGthep ACHTUNGTRENNUNGsin protease
activities and therefore represents a novel class of ABPs.
Experimental Section
General methods : Unless otherwise noted all resins and reagents
were purchased from commercial suppliers and used without fur-
ther purification. All solvents used were of HPLC grade. Reversed-
phase HPLC was conducted on a C18 column by using an PKTA ex-
plorer 100 (Amersham Pharmacia Biotech). LC-MS data were ac-
quired by using an API 150EX system (Applied Biosystems).
Synthesis : See Supporting Information for detailed description of
the synthetic procedures.
Competition in whole proteomes : Rat-liver homogenates were
used (1 mgmL1) in an acetate buffer (50 mm, pH 5.5). Samples
were incubated with the indicated concentrations of inhibitor at
room temperature for 0.5 h and subsequently treated with radiola-
beled DCG-04 (106 cpm) for an additional 0.5 h prior to subjection
to gel-electrophoresis (12% polyacrylamide). Visualization of pro-
tease activities was performed by using a Typhoon Scanner for
phosphorimaging. Data were quantified by using NIH ImageJ and
analyzed with GraphPad Prism.
For competition in P. falciparum, synchronized cultures of the para-
site were harvested at the trophozoite stage for optimal labeling
of all three falcipains[5] after saponin lysis of host red-blood cells.
Parasite pellets were lyzed by addition of NP40 (1%) at pH 5.5. The
insoluble fraction (40 mg) was used in each competition reaction,
which was incubated with inhibitor dilutions for 0.5 h and then
treated with radiolabeled DCG-04 for 1 h. Visualization and quanti-
tation were performed as described above.
Kinetic experiments : Inhibition kinetics of caACHTUNGTRENNUNGthepACHTUNGTRENNUNGsins B and L
were determined under pseudo first-order conditions with at least
tenfold molar excess of inhibitors as described previously.[13b] Con-
centration of caACHTUNGTRENNUNGthep ACHTUNGTRENNUNGsins in the assay was 1 nm (ca ACHTUNGTRENNUNGthepACHTUNGTRENNUNGsin L) and
10 nm (ca ACHTUNGTRENNUNGthepACHTUNGTRENNUNGsin B). Ca ACHTUNGTRENNUNGthep ACHTUNGTRENNUNGsin activity was measured in the pres-
ence of fluorogenic substrate Z-RR-AMC (10 mm ; Bachem, Torrance,
CA) for caACHTUNGTRENNUNGthep ACHTUNGTRENNUNGsin B and Z-FR-AMC (10 mm ; Bachem) for caACHTUNGTRENNUNGthep ACHTUNGTRENNUNGsin L.
The concentration of DMSO during the measurement never ex-
ceeded 2.5%. The increase of fluorescence (370 nm exitation,
460 nm emission) was continuously monitored with a Spectra-
max M5 fluorescent plate reader (Molecular Devices, Sunnyvale,
CA).
For irreversibility experiments, ca ACHTUNGTRENNUNGthepACHTUNGTRENNUNGsin L or B (20 nm) were incu-
bated with inhibitor (2 mm) for 2 h at room temperature. Subse-
quently, the inhibitor was diluted by repeated washing/filtration
steps over a Microcon YM-10 centrifugal filter (Millipore), so that
free inhibitor concentration was less than 4 nm. Next, the activity
of enzymes was measured as described.[13b]
Mass spectrometry : Purified ca ACHTUNGTRENNUNGthepACHTUNGTRENNUNGsin L (approximately 5 mm) was
incubated with the indicated inhibitors (20 mm ; diluted from a
1000x stock in DMSO) or with control DMSO at pH 5.5 (5 mm
sodium acetate) for 1 h. MALDI-TOF analysis was performed on a
Bruker Ultraflex MALDI-TOF/TOF spectrometer of the Stanford Pro-
teomics & Integrative Research Facility.
Biotin blots : Purified bovine spleen ca ACHTUNGTRENNUNGthepACHTUNGTRENNUNGsin B (100 ng; Calbio-
chem) or recombinant human ca ACHTUNGTRENNUNGthepACHTUNGTRENNUNGsin L (a kind gift from the
Turk laboratory, Ljubljana, Slovenia) were incubated at room tem-
perature with indicated concentrations of biotinylated ABP for
30 min (50 mm acetate buffer, pH 5.5, 1% DMSO, 5 mm MgCl2, with
or without 2 mm DTT). After addition of either reducing (150 mm
DTT) or nonreducing sample buffer, mixtures were run on a poly-
acrylamide gel and transferred to a nitrocellulose membrane. Bio-
tinylated proteins were detected by using VectaStain reagents
(Vector Labs, Burlingame, CA) and visualized on film by chemolu-
minescence.
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